echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Please the United States, India will slow down the pace of drug prices

    Please the United States, India will slow down the pace of drug prices

    • Last Update: 2014-09-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: new Kangjie September 26, 2014 this is the third article of "Indian pharmaceutical industry series" specially launched by new Kangjie You can read a collection of previous articles in reply to "India" The Indian government's control over the price of essential drugs has deeply hurt local enterprises and foreign pharmaceutical giants In May this year, the Indian government increased some varieties on the basis of the original price limit of 350 kinds of drugs, and reduced the prices of some varieties by as much as 80% The move angered the entire pharmaceutical industry However, recently, Prime Minister Narendra modi has further strengthened the control of the National Drug Pricing Authority (NPPA), which shows that he may take a more moderate approach to drug price reduction than his predecessors India's NPPA is in charge of setting and guiding the price of basic drugs in the country At the moment, the right is withdrawn, which is somewhat surprising to the outside world On Monday, NPPA announced that it had lost the right to unilaterally supplement the quantity of drugs with limited price, but it did not explain why However, the increase of the list of 108 drugs with limited price in July has been protested by the whole industry Last week, the agency added more than 30 drugs to its list of essential drugs The Indian Association of pharmaceutical manufacturers has expressed strong opposition to this and has filed a public prosecution In India, 70% of the population lives on less than $2 a day, while 80% do not have health insurance Therefore, the government has a strong incentive to implement the drug price limit policy However, for the pharmaceutical industry, including the large Indian pharmaceutical companies, such as lambertino, sunpharma, let alone the western multinational pharmaceutical giants, such as Sanofi, Abbott, Pfizer and MSD, have been arguing about this "India's drug prices are already the lowest in the world, and low-cost drug policies simply do not guarantee the minimization of the government's social costs." An unnamed NPPA official previously told Reuters that the prime minister's direct control of NPPA has affected the implementation of pricing policy, but for now, the past is the past, and the reduced drug price cannot go back "The foundation for further progress is gone, and we are not willing to say anything to the past There is always an overwhelming power in government " The Indian government has no explanation for the right to cut NPPA Reuters said the move, announced just days before the Indian Prime Minister's visit to the United States, seemed to please the U.S government Tensions between India and the United States have been going on for some time, with the focus on the radical forced imitation of pharmaceutical patents by the Indian government in the past For example, the government has imposed a copy license on the Indian pharmaceutical company NATO, and is also considering issuing it to other local pharmaceutical companies A similar situation occurred in the patent protected antitumor drug of Pfizer, sotan The compulsory issuance of drugs under patent protection has greatly reduced the image of the Indian government in the eyes of multinational pharmaceutical companies The U.S government, under pressure from its pharmaceutical companies, has included India in the list of countries with patent protection problems Subtle changes in India's drug policy, whether to slow down or continue to push forward, we will follow up the report.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.